Bergin, Christopher J.
Zouggar, Aïcha
Mendes da Silva, Amanda
Fenouil, Tanguy
Haebe, Joshua R.
Masibag, Angelique N.
Agrawal, Gautam
Shah, Muhammad S.
Sandouka, Tamara http://orcid.org/0000-0002-0832-5753
Tiberi, Mario http://orcid.org/0000-0002-6496-4488
Auer, Rebecca C. http://orcid.org/0000-0002-3617-0015
Ardolino, Michele
Benoit, Yannick D. http://orcid.org/0000-0002-6677-4020
Funding for this research was provided by:
Cancer Research Society (942363)
Ontario Ministry of Research, Innovation and Science (ER17-13-12)
Gouvernement du Canada | Canadian Institutes of Health Research (PJT-17354, 201302MFE-300637-197755)
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (RGPIN-2018-06521)
Article History
Received: 28 June 2022
Accepted: 11 January 2024
First Online: 13 February 2024
Competing interests
: Relatives of Y.D.B. hold shares in Gibiex Biotech. M.A. received monetary compensation from Alloy Therapeutics for consulting. M.A. is under a contract agreement to perform sponsored research with Actym Therapeutics and Dragonfly Therapeutics. Neither consulting nor sponsored research is related to the present article. The other authors declare no competing interests.